Our Stocks to Watch today include Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP), BigString Corporation (OTCBB: BSGC), Rapid Link, Inc. (OTCBB: RPID), Paradigm Medical Industries, Inc. (OTCBB: PMED), TrendSetter Solar Products, Inc. (OTC: TSSP), Aethlon Medical, Inc. (OTCBB: AEMD)
Visit http://www.otcpicks.com/ to register for our Daily Market Mover’s Digest Newsletter, and Email Stock Watch Alerts.
RENHUANG PHARMACEUTICALS (OTCBB: RHGP)
Detailed Quote: http://www.otcpicks.com/quotes/RHGP.php
Company Profile: http://www.otcpicks.com/renhuang-pharma/renhuang-pharma.htm
Renhuang Pharmaceuticals, located in Harbin of Heilongjiang Province in Northeast China, is a leading integrated developer, manufacturer and distributor of a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products. The Company provides three major product lines including the Acanthopanax-based natural medicinal products, Shark Power Health Care series and Traditional Chinese Medicines. Renhuang's key product line is Acanthopanax-based products, an effective natural medicine in treating depression and melancholy and offering various other health benefits. By controlling an estimated 70% of China's natural resource of Acanthopanax (also known as Siberian Ginseng), the Company has a dominant market position in Acanthopanax-based natural medicines. The Company distributes its products through a multi-layer sales network of over 2000 sales agents. Its products are not only sold nationwide but also exported to Russia and Southeast Asia. Renhuang has established a multi-channel research and development infrastructure composed of in-house researchers, a post-doctoral working center, and collaboration with well known institutions and scientists. In manufacturing, the Company strictly follows the international GMP certified quality standards and system by utilizing cutting-edge technologies, the state of the art equipment, and the proprietary innovative and award winning processes. For more information about Renhuang Pharmaceuticals, visit http://www.renhuang.com/.
RHGP News:
January 22 - Renhuang Pharmaceuticals Announces Breakthrough in Study of New Form of Anti-Depression Chinese Medicine: Lyophilized Syringin Powder for Injection
Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP) (“Renhuang” or the “Company”), a leading Chinese integrated drug developer, manufacturer and distributor, announced the successful laboratory production of lyophilized syringin powder, its new powder injection anti-depression and fatigue drug. Renhuang expects this new drug to become its next revenue growth driver. At 90% purity, the syringin portion in the sample drugs meets the criteria of the State Food and Drug Administration (SFDA). Renhuang is expected to soon start clinical trials to evaluate both the efficacy and the safety of this new drug for depression and fatigue patients.
Lyophilized syringin powder for injection is developed independently by Renhuang as a new form of pure Chinese herbal medicine that does not have any of the side-effects of other synthetic anti-depression drugs commonly used by patients around the world. Renhuang is in the process to file an invention patent application for this new drug with the State Intellectual Property Office of the P.R.C (SIPO). The product is expected to be classified as a “Class One” new drug by SFDA representing a major breakthrough in anti-depression drug development worldwide. This new drug can also be used as anti-exhaustion treatment, wound stancher and healthy gland growth nutrition.
Mr. Li Shaoming, chief executive officer of Renhuang, said, “ Although rapid economic development is raising standards of living in China and improving the lives of many, Chinese people are increasingly confronted with stress brought about by economic development and increased competition. At the same time, they are becoming more health conscious and more sophisticated in their understanding of medical treatments. Given the high risks of side effects from current anti-depression drugs, both physicians and patients around the world are yearning for anti-depression medication treatments with low or zero side-effects. This creates substantial market potential globally for our new anti-depression drug. We are very confident that this new drug will not only help Renhuang expand its market share in China but it will also increase Renhuang’s brand awareness overseas.”
By controlling an estimated 70% of China’s natural resource of Acanthopanax (also known as Siberian Ginseng), a raw material, from which syringin is extracted, securing ample supply for the new drug and minimizing raw material cost.
According to a 2006 report by the World Heath Organization, there were about 340 million people suffering from depression in the world including more than 26 million in China as per the latest statistics from the China Association for Mental Health. Global sales of anti-depression drugs reached US $20.60 billion in 2006.
Renhuang has secured prime time advertising slots on China Central Television Station (CCTV) in 2008. Advertising during the Beijing Olympics, in particular, will provide a unique platform to substantially increase Renhuang’s brand recognition in China and around the world.
BIGSTRING CORPORATION (OTCBB: BSGC)
Detailed Quote: http://www.otcpicks.com/quotes/BSGC.php
Company Profile: http://www.otcpicks.com/bigstring/bigstring.htm
BigString Corporation, through its subsidiary, BigString Interactive, Inc., provides email services. It offers BigString, which is a Web-based, POP3 server email service solution that allows the user to edit, recall, cancel, and erase the email, as well as insert or delete attachments, even after the email has been sent out and opened. The company also provides BigString Beta 2.0 that offers erasable, recallable, and self destroying applications, non-printable and non-forwardable emails, set time or number of views, and masquerading to protect the sender's privacy and security. BigString Beta 2.0 also provides spam filters, virus protection, and large-storage web-based email accounts. The company's products include BigString Free, which provides the features of BigString Beta 2.0, and includes 1GB of storage and permits the user to send unlimited emails per month; BigString Premium, which offers the features of the BigString Free account, plus vanity domains, POP3 access using any email client, 2GB of storage, and 30 minute video email; and BigString Business that offers the features of the BigString Premium account, plus 10 email accounts, 20GB of storage, global filter notification, and email management. BigString Corporation also offers BigString Marketer Pro, which provides an enterprise marketing software application which allows for the sending of interactive video email commercials that can be programmed to self-destruct at a set time; and BigString Marketer SMB, a hosted video email marketing platform for small and medium size businesses. The company was founded in 2003. It was formerly known as Recall Mail Corporation and changed its name to BigString Corporation in 2005. Bigstring Corporation is based in Red Bank, New Jersey.
BSGC News:
January 23 - BigString Corporation Launches Video Email for Chinese Market
BigString Corporation (OTCBB: BSGC) announced that it is launching a new video email platform for the Chinese market through its BigString.cn and BigString.com.cn websites. This service will allow users of both the traditional and simplified language Chinese BigString websites to send video emails up to 30 minutes in length that can be set to self-destruct after a predetermined number of views.
“The popularity of video as means to communicate, in combination with one of the fastest-growing internet markets in the world, creates a significant new market opportunity for BigString” stated Darin Myman, President and CEO of BigString Corporation. Myman also noted that BigString “will continue to innovate communication privacy initiatives and seek distribution partnerships for the global market.”
RAPID LINK INCORPORATED (OTCBB: RPID)
"Up 20.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/RPID.php
Rapid Link, Incorporated, together with its subsidiaries, provides a range of international telecommunications services to individual customers, as well as small and medium sized enterprises in the United States and internationally. Its services include the transmission of voice and data traffic over public and private networks. The company offers an Internet-based communication service that works over high-speed Internet connection utilizing an Internet access device to connect customers to its Rapid Link network software, which enables VoIP communications; and international “Dial Thru” and “Re-origination” services that enable customers to make local and/or international calls. Rapid Link also provides international call completion on a wholesale basis to telecommunications companies; global roaming service, which offers customers a single account number to initiate phone-to-phone calls using specific toll-free access numbers; and traditional 1+ long distance service to business and residential users. The company was founded in 1986. It was formerly known as Canmax, Inc. and changed its name to ARDIS Telecom & Technologies, Inc. in 1999. Further, it changed its name to Dial Thru International Corporation in 2000 and to Rapid Link, Incorporated in 2005. Rapid Link is headquartered in Los Angeles, California.
RPID News:
January 23 - Rapid Link Announces Fiscal Year 2007 Financial Highlights
Revenues of Over $17 Million, Positive Cash Flow From Operations of Over $650 Thousand, and Gross Profit of $4.7 Million; Rapid Link Reaches Profitability Goals in Line With Management's Expectations
Rapid Link, Inc. (OTCBB: RPID), one of the leading providers of diversified communications services to certain niche markets, announced financial results for its fiscal year ended October 31, 2007.
FISCAL YEAR 2007 HIGHLIGHTS:
* Revenues increased $4 million to $17,326,035, or 30%, as compared to fiscal 2006.
* Gross profit increased to over $4.7 million, or 29%, as compared to fiscal 2006; general and administrative expenses decreased $192,000, or 5%, as compared to fiscal 2006.
* $659,000 of positive operating cash flow generated and net income positive in 4th quarter.
With over 15,000 customers worldwide and approximately $20 million in run-rate revenues, Rapid Link is poised to grow with technologies, further serve our customer base of customers and expand into new markets. We have fully integrated Telenational Communications into our operations, and recently completed the asset purchase of Web-Breeze Networks and Communications Advantage, which include a wireless broadband network.
"Our goal is to provide the best overall communications experience, to both business and residential customers at affordable prices. Whether it's a digital phone call, or merely surfing the internet, we strive to provide the best service available," said John Jenkins, Rapid Link's Chairman and Chief Executive Officer. Mr. Jenkins further stated, "Rapid Link continues to improve its fundamentals and remains focused on maintaining profitability, increasing revenues and expanding Rapid Link's bundle of service offerings." "Rapid Link revenues have shown tremendous growth over the past fiscal year, while also meeting management's profitability goals as a result of acquisition integrations and cost reductions," stated Chris Canfield, Rapid Link's President and Chief Financial Officer.
Excluding non-cash items, net loss to common stockholders for the year ended October 31, 2007 was $13,031 vs. a net loss to common stockholders of $1,023,963 for the previous year ended October 31, 2006, representing over a $1 million improvement. For fiscal year 2007, Rapid Link incurred $1,076,350 in non-cash interest expense. Additional non-cash items incurred during the year include depreciation and amortization expense, share-based compensation expense, bad debt expense, partially offset by a gain on legal settlements.
Net loss before non-cash items is not a term defined by generally accepted accounting principles (GAAP) and may not be comparable to other similarly titled measurements used by other companies. Such non-GAAP measures should be considered in addition to, and not as a substitute for, performance measures calculated in accordance with GAAP. The accompanying table includes a detailed reconciliation of net loss reported in accordance with GAAP to net loss before non-cash items.
PARADIGM MED INDUSTRIES (OTCBB: PMED)
"Up 15.38% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/PMED.php
Paradigm Medical Industries, Inc. engages in the design, development, manufacture, and sale of technology surgical and diagnostic eye care products. Its diagnostic products include P55, P2200, and P2500 pachymetric analyzer; P20 and P2000 A-scan biometric ultrasound analyzer; P37, P37-II, and P2700 A/B scan ocular ultrasound diagnostic product; P40 UBM ultrasound biomicroscope; P45 UBM ultrasound biomicroscope; P60 UBM ultrasound biomicroscope; BFA ocular blood flow analyzer and disposables; CT 200 corneal topography system; LD 400 autoperimetry system; and TKS 5000 autoperimetry system. The company's products also comprise Precisionist Thirty Thousand and Photon laser, which have ocular surgery workstation with surgical equipment and disposables. Paradigm's surgical products are systems for use by ophthalmologists to perform surgical treatment procedures to remove cataracts. It markets its products through direct sales representatives, independent sales representatives, and ophthalmic product distributors in the United States, as well as through a network of dealers internationally. The company was founded in 1989 and is based in Salt Lake City, Utah.
PMED News:
January 23 - Paradigm Medical Industries Settles Last of Active Lawsuits
Paradigm Medical Industries, Inc. (OTCBB: PMED), a leader in glaucoma diagnostic and management devices, announced that it has settled the last of its currently active lawsuits against the Company. The Company disclosed it had reached an out-of-court settlement with Larry Hicks, a former consultant. Terms were not disclosed.
In 2006, Paradigm Medical resolved two suits filed by former employees via summary judgments in favor of the Company. Paradigm Medical also resolved several class-action suits out of court in 2005. All of these lawsuits, including Hicks and the class action suits, were filed in 2003.
“We can now fully concentrate on our core business of developing, manufacturing and marketing of diagnostic glaucoma equipment that we provide to the ophthalmic industry,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. “Management has spent substantial time defending the Company in these suits. We can now have full focus in implementing our strategies and business plan.”
TRENDSETTER SOLAR PRODUCTS (OTC: TSSP)
"Up 22.22% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/TSSP.php
TrendSetter Solar Products, Inc. is a quality manufacturer of solar hot water heating and storage systems in the United States. TrendSetter's solar hot water systems and storage tanks are uniquely positioned to serve the residential and commercial market. The Company offers a comprehensive range of solar water heating solutions, including solar radiant floor heating options, which are rated and qualify for the new federal energy tax credit program. A standard residential hot water heater emits approximately one and a half tons of carbon dioxide and carbon monoxide into the atmosphere. TrendSetter's solar hot water heating and storage systems are emissions free. As global warming and alternate and renewable energies become more of a concern, TrendSetter's products are one of the answers. Additional information can be seen at the Company's website: http://www.trendsetterindustries.com/.
TSSP News:
January 23 - TrendSetter Solar Products Increases Importation of Its Evacuated Tube Solar Hot Water Collectors in 2008
TrendSetter Solar Products, Inc. (OTC: TSSP) announced it is stepping up importation of its new Evacuated Tube Solar Hot Water Collectors into the United States. The Company received the first full twenty-foot container of its new collector in the U.S. last week. The new evacuated tube collector has begun to ship to projects primarily based on the West Coast.
The Company has placed orders for one container a month over the next quarter in order to meet expected sales demand. Each container will contain approximately 45 complete TrendSetter® Evacuated Tube collectors. As the demand for new collectors is expected to increase, TrendSetter® will be able to double the number of monthly containers to approximately 80 collectors per month. Collector sales at the current rate are expected to contribute $1 to $2 million to the Company’s sales volume in 2008.
TrendSetter is also anticipating the Solar Rating Certification Corporation (SRCC) certification for the new collector to be issued by April of 2008. The application for SRCC certification was initiated in July of 2007. SRCC Certification is required for the Federal Tax Credits and State Rebates.
TrendSetter CEO, Dirk Atkinson, stated, “The new collector is superior in quality to similar collectors currently on the market. TrendSetter has completed transitioning from selling other brands of evacuated tube collectors to the new TrendSetter Brand Collector in December 2007. From now as we are selling Evacuated Tube Collectors they will be TrendSetter’s. This commitment to standing monthly orders is important, because the product availability will build customer confidence in the TrendSetter brand.”
TrendSetter® also announced last June that it had contributed a six collector array to the 2007 Sunset Magazine Idea House, located at 3027 25th Street, in San Francisco, CA. The Sunset Magazine Idea House is currently offering tours where TrendSetter’s solar hot water system, including the new collectors, may be viewed. For more information on the Sunset Magazine Idea House go to:
http://www.sunset.com/sunset/marketplace/article/0,20633,1574303%7E.
AETHLON MEDICAL INCORPORATED (OTCBB: AEMD)
"Up 9.98% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/AEMD.php
Aethlon Medical, Inc. engages in the research and development of a medical device known as the Hemopurifier that removes harmful substances from the blood. The company's Hemopurifier platform technology is designed to reduce the presence of infectious viruses and other toxins from human blood. It focuses on developing therapeutic devices to treat acute viral conditions caused by pathogens targeted as potential biological warfare agents, and chronic viral conditions, including HIV/AIDS and Hepatitis-C. The company was founded in 1991 and is headquartered in San Diego, California.
AEMD News:
January 22 - The Aethlon Hemopurifier(R) Proves Effective in Capturing Bird Flu Virus
Aethlon Medical, Inc. (OTCBB: AEMD), a pioneer in developing therapeutic devices for infectious disease, disclosed that researchers have demonstrated the effectiveness of the Aethlon Hemopurifier® in capturing the highly-fatal H5N1 strain of the Avian Flu Virus (Bird Flu.) In pre-clinical studies, high concentrations of H5N1 flu virus (~ 3 million flu virus/ml) were observed to be rapidly depleted from cell culture fluids when circulated through the Hemopurifier®. The study data indicated that during a six-hour testing period, the Hemopurifier® removed up to 99.4 percent of infectious H5N1 flu virus. Verification of viral capture was documented by both real-time PCR and conventional plaque assay (TCID 50) measurements.
“The data provides real hope for a post-infection treatment against pandemic influenza and further reinforces the ability of our Hemopurifier® to address a broad spectrum of viral conditions,” stated James A. Joyce, Chairman and CEO of Aethlon Medical. “Additionally, it appears possible that the use of the Hemopurifier® could open the door for drugs previously considered incapable of providing clinical benefit as a stand-alone therapy.”
The Aethlon Hemopurifier® is a medical device designed for the single use removal of infectious viral pathogens from blood. The device, which augments the natural immune response of clearing infectious viruses and toxins before cell and organ infection, is positioned to fill a void in treating drug and vaccine resistant infectious diseases. In order to further support the use of the Hemopurifier® as a broad-spectrum treatment countermeasure against bioterror and pandemic threats in the United States, Aethlon will include this new data in a forthcoming submission to the U.S. Department of Health and Human Services (HHS) and the newly established Biomedical Advanced Research and Development Authority (BARDA.) Based on the significance of the H5N1 data and the continued demonstration of safety in human studies, Aethlon may on a limited basis provide the Hemopurifier® to countries that request the Hemopurifier® as a treatment option for infected citizens. Researchers at the Battelle Biomedical Research Center conducted the H5N1 studies.
It is feared that the H5N1 strain of avian influenza virus, whose mortality rate in infected humans exceeds 60 percent, will spark a global epidemic should it evolve to allow for an efficient spread of host-to-host infections in humans. The recent discovery that H5N1 avian influenza virus can spread via the bloodstream to organs and other regions of the body typically not attacked by influenza viruses explains in part, the high virulence of H5N1 infection and why it remains a serious pandemic threat. The ability of H5N1 virus to proliferate in blood represents a causative effect for triggering hypercytokinemia (cytokine storm), a direct parallel to the Spanish Flu of 1918, which reportedly killed up to 40 million people within 20 months. Though governments and health agencies are stockpiling antiviral drugs to treat influenza, these therapies have yet to demonstrate effectiveness against human H5N1 infection. A further complication to drug treatment has arisen from the clinical observation that drug absorption appears impaired in severely ill H5N1 patients, and in H5N1 patients with gastrointestinal symptoms.
Researchers believe the removal of circulating H5N1 hemagglutinin, a surface protein that is deleterious to the host and immune system, combined with the removal of infectious H5N1 virus would be clinically beneficial to infected patients. Corresponding to this belief, the Hemopurifier® targets the rapid removal of both infectious H5N1 virus and immunosuppressive H5N1 hamagglutinin from circulation. As a result, Aethlon believes the Hemopurifier® is positioned to benefit infected patients, both as a stand-alone therapeutic, and as an adjunct treatment able to improve the clinical benefit of other candidate therapies.
ABOUT BATTELLE BIOMEDICAL RESEARCH CENTER
Battelle Biomedical Research Center is a research group in the National Security Global Division of Battelle Memorial Institute, an organization that provides solutions to some of the world's most important challenges through its three global businesses: National Security, Energy Science and Technology, and Health and Life Sciences. Battelle is the world's largest independent research and development organization with technology contributions that find their way into hundreds of commercial products each year. Conducting multi-billion dollars in global R&D annually, Battelle oversees over 20,000 employees in more than 120 locations worldwide, including five national laboratories that Battelle manages or co-manages for the U.S. Department of Energy. Battelle was recently approved by the Department of Health and Human Services (HHS) under the Select Agent Programs of the Centers for Disease Control and Prevention (CDC) and the Animal and Plant Health Inspection Service (APHIS) to carry out studies on highly pathogenic avian influenza, including the H5N1 strain. Battelle was established in 1929 as a non-profit charitable trust and is headquartered in Columbus, Ohio. For more information, visit http://www.battelle.org/.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover’s Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated eight thousand dollars by a third party (StockPromoters.com) for RHGP advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor’s sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
